Taiwan FDA accepts Everest’s NDA for xerava to treat intra-abdominal infections
The new fully synthetic fluorocycline intravenous antibiotic, xerava has been developed to use as a first-line empiric monotherapy to treat multidrug resistance (MDR) infections, such as MDR Gram-negative